TY - JOUR
T1 - Diagnostic delays are common among patients with hepatocellular carcinoma
AU - Patel, Nishant
AU - Yopp, Adam C.
AU - Singal, Amit G.
N1 - Funding Information:
This work was conducted with support from NIH/NCATS Grant UL1-TR000451. Dr. Singal was supported in parts by a grant from the AHRQ R24 HS022418 and the UT Southwestern Center for Patient-Centered Outcomes Research.
Funding Information:
This work was conducted with support from NIH/NCATS Grant UL1-TR000451. Dr. Singal was supported in parts by a grant from the AHRQ R24 HS022418 and the UT Southwestern Center for Patient-Centered Outcomes Research. The content is solely the responsibility of the authors and does not necessarily represent the official views of UT-STAR, the UT Southwestern Medical Center and its affiliated academic and health care centers, the National Center for Advancing Translational Sciences, or the NIH. Correspondence: Amit G. Singal, MD, MS, Division of Digestive and Liver Diseases, University of Texas Southwestern Medical Center, 5959 Harry Hines Boulevard, POB 1, Suite 420, Dallas, TX 75390-8887. E-mail: amit.singal@utsouthwestern.edu
Publisher Copyright:
© JNCCN - Journal of the National Comprehensive Cancer Network.
PY - 2015/5/1
Y1 - 2015/5/1
N2 - Background: Most patients with hepatocellular carcinoma (HCC) present at advanced stages. The prevalence and clinical impact of delays during diagnostic evaluation among patients with HCC is unclear. Purpose: To identify and characterize factors associated with diagnostic delays among patients with HCC. Methods: Records were reviewed for consecutive patients with cirrhosis and HCC at a large urban hospital between January 2005 and July 2012. Time from presentation to diagnosis was determined using Kaplan-Meier analysis. Diagnostic delay was defined as time to diagnosis exceeding 3 months, and multivariate logistic regression was used to identify correlates of diagnostic delays. Results: Among 457 patients with HCC, 226 (49.5%) were diagnosed as outpatients. Among these, median time-to-diagnosis was 2.2 months, with 87 patients (38.5%) experiencing a diagnostic delay. Diagnostic delays were positively associated with the presence of hepatic encephalopathy (odds ratio [OR], 2.29; 95% CI, 1.03-5.07) and negatively associated with presentation after implementation of the electronic medical records (EMR) (OR, 0.28; 95% CI, 0.15-0.52) and presentation with an abnormal ultrasound (OR, 0.36; 95% CI, 0.19-0.67) on multivariate analysis. Higher rates of diagnostic delays were observed among those with hepatic encephalopathy (56% vs 35%), whereas lower rates were seen in those who presented after EMR implementation (26% vs 60%) and those who presented with an abnormal ultrasound with or without an elevated alpha fetoprotein level (27% vs 50%). Among 49 patients with mass-forming HCC and diagnostic delay, 18% had interval tumor growth of 2 cm or greater. Conclusions: Nearly 20% of patients with HCC wait more than 3 months from presentation to diagnosis, which can contribute to interval tumor growth.
AB - Background: Most patients with hepatocellular carcinoma (HCC) present at advanced stages. The prevalence and clinical impact of delays during diagnostic evaluation among patients with HCC is unclear. Purpose: To identify and characterize factors associated with diagnostic delays among patients with HCC. Methods: Records were reviewed for consecutive patients with cirrhosis and HCC at a large urban hospital between January 2005 and July 2012. Time from presentation to diagnosis was determined using Kaplan-Meier analysis. Diagnostic delay was defined as time to diagnosis exceeding 3 months, and multivariate logistic regression was used to identify correlates of diagnostic delays. Results: Among 457 patients with HCC, 226 (49.5%) were diagnosed as outpatients. Among these, median time-to-diagnosis was 2.2 months, with 87 patients (38.5%) experiencing a diagnostic delay. Diagnostic delays were positively associated with the presence of hepatic encephalopathy (odds ratio [OR], 2.29; 95% CI, 1.03-5.07) and negatively associated with presentation after implementation of the electronic medical records (EMR) (OR, 0.28; 95% CI, 0.15-0.52) and presentation with an abnormal ultrasound (OR, 0.36; 95% CI, 0.19-0.67) on multivariate analysis. Higher rates of diagnostic delays were observed among those with hepatic encephalopathy (56% vs 35%), whereas lower rates were seen in those who presented after EMR implementation (26% vs 60%) and those who presented with an abnormal ultrasound with or without an elevated alpha fetoprotein level (27% vs 50%). Among 49 patients with mass-forming HCC and diagnostic delay, 18% had interval tumor growth of 2 cm or greater. Conclusions: Nearly 20% of patients with HCC wait more than 3 months from presentation to diagnosis, which can contribute to interval tumor growth.
UR - http://www.scopus.com/inward/record.url?scp=84984573555&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84984573555&partnerID=8YFLogxK
U2 - 10.6004/jnccn.2015.0074
DO - 10.6004/jnccn.2015.0074
M3 - Article
C2 - 25964640
AN - SCOPUS:84984573555
SN - 1540-1405
VL - 13
SP - 543
EP - 549
JO - JNCCN Journal of the National Comprehensive Cancer Network
JF - JNCCN Journal of the National Comprehensive Cancer Network
IS - 5
ER -